Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14JUN

FCA and PRA cut SM&CR certification by 15%

3 min read
16:35UTC

Phase one of a 50% reduction target. The single biggest regulatory overhead on small authorised fintechs has finally started to shrink.

TechnologyDeveloping
Key takeaway

UK fintech's single biggest compliance overhead is shrinking for the first time since 2019.

The Financial Conduct Authority (FCA) and Prudential Regulation Authority (PRA) cut certification roles under the Senior Managers and Certification Regime (SM&CR) by 15% on 22 April 2026, phase one of a 50% reduction target. The two regulators also confirmed that the Certification Regime will be removed from primary legislation over time, a structural change rather than a temporary loosening.

SM&CR requires authorised financial firms to individually certify fitness and propriety for every senior and customer-facing employee, each year, with personal regulatory accountability attached to the sign-off. Since its 2019 expansion to all authorised firms, it has been the single largest compliance overhead for small fintechs; a twenty-person payments startup runs the same certification cycle as a 200-person bank. Removing 15% of roles from scope is the first material reduction in that overhead in six years. Phase two takes the cut to 50%.

The FCA and PRA timed the cut to land in the same week as the AI Live Testing second-cohort expansion and alongside the British Business Bank direct-investment mandate. The combined signal to UK fintech is coherent: lower authorised-firm overhead, wider permitted AI experimentation scope, continuing authorisation pipeline capacity. Founders running authorised fintechs at sub-50-headcount will see the concrete effect at the next compliance cycle renewal.

Deep Analysis

In plain English

The Senior Managers and Certification Regime (SM&CR) is a set of rules that requires financial services companies to personally certify that their key staff are fit and proper for their roles, and to hold specific senior managers personally accountable for regulatory failures. It was created after the 2008 financial crisis to ensure that individual bankers could be held responsible rather than just the banks themselves. For small fintech startups, it became a significant administrative burden. The 15% reduction announced this week means fewer roles need to be formally certified, which reduces some paperwork and legal costs for smaller authorised firms.

Deep Analysis
Root Causes

The SM&CR 2019 extension to solo-regulated firms created certification obligations for roles; including some client-service and operations roles at small fintechs; that had no equivalent in the banking sector regime the scheme originally targeted; removing those roles in phase one is a correction of an over-extension rather than a deregulatory choice.

The FCA's Growth and Competitiveness objective, added to its statutory mandate by the Financial Services and Markets Act 2023, creates an explicit duty to consider the competitive impact of regulation; the SM&CR reform is the first material action taken under that duty in fintech, and the scale of the first phase (15% of roles) reflects caution about moving ahead of a 2026-27 Parliamentary review of the Financial Services and Markets Act.

What could happen next?
  • Consequence

    The 50% total certification-role reduction target requires a further 35-percentage-point cut beyond today's phase one; HMRC's autumn 2026 consultation on the Certification Regime's removal from primary legislation is the mechanism for that reduction, and the outcome of that consultation will determine whether the 50% target is reached before the next election.

  • Opportunity

    Fintech firms that currently maintain inflated certification-role counts to protect against regulatory interpretation risk; a common practice identified in Linklaters' survey; will use the phase-one reforms as an opportunity to normalise their compliance structures, producing a one-off audit and legal spend in 2026 followed by structural cost savings from 2027.

First Reported In

Update #2 · Britain's innovation pipe leaks at both ends

CNBC· 22 Apr 2026
Read original →
Causes and effects
This Event
FCA and PRA cut SM&CR certification by 15%
The SM&CR 15% cut is the first material reduction in fintech compliance overhead since the regime was expanded in 2019, paired with a sandbox demand surge that suggests a deliberate regulatory-posture shift.
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.